Home | All trials

[RDF data]
Trial NCT00000388

Resource URI: http://static.linkedct.org/resource/trials/NCT00000388
PropertyValue
linkedct:acronym MTA
linkedct:brief_title Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA)
linkedct:condition <http://static.linkedct.org/resource/condition/12664>
linkedct:condition <http://static.linkedct.org/resource/condition/1326>
linkedct:condition <http://static.linkedct.org/resource/condition/4169>
linkedct:criteria Inclusion Criteria: - Patients must have: Rigorously diagnosed Attention Deficit Hyperactivity Disorder (ADHD).
linkedct:description This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes. In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_maximum_age 9 Years
linkedct:eligibility_minimum_age 7 Years
linkedct:end_date November 1999
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date November 2, 1999
linkedct:id NCT00000388
rdfs:label Trial NCT00000388
linkedct:lastchanged_date March 26, 2008
linkedct:lead_sponsor_agency National Institute of Mental Health (NIMH)
linkedct:nct_id NCT00000388
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Multimodal Treatment Study of Children With ADHD
linkedct:org_study_id MH50453
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/23049>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/25213>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/34394>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/55775>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/61346>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/7213>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000388>
linkedct:phase Phase 4
linkedct:results_reference <http://static.linkedct.org/resource/results_reference/2154>
linkedct:secondary_id DSIR CT
linkedct:secondary_id MH50440
linkedct:secondary_id MH50447
linkedct:secondary_id MH50454
linkedct:secondary_id MH50461
linkedct:secondary_id MH50467
linkedct:source National Institute of Mental Health (NIMH)
linkedct:start_date September 1998
linkedct:study_design Treatment, Randomized
linkedct:study_type Interventional
linkedct:summary This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes. In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment. A child may be eligible for this study if he/she: Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).
rdf:type linkedct:trials
linkedct:verification_date March 2008